1. Home
  2. News Archive

More News

2025-2026 Ophthalmic Meetings Calendar
2025-2026 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Spinogenix Unveils Glaucoma Program to Evaluate Once-Daily Neuroprotective Pill
Spinogenix Unveils Glaucoma Program to Evaluate Once-Daily Neuroprotective Pill

Los Angeles-based Spinogenix reported Oct. 16 that it was launching a program to evaluate SPG302 as a potential neuroprotective therapeutic for glaucoma. Spinogenix describes SPG302 as a once-a-day...

Eyenuk, AAO Collaborate to Offer AI-Driven DR Screening for Underserved Patients in Delaware
Eyenuk, AAO Collaborate to Offer AI-Driven DR Screening for Underserved Patients in Delaware

Eyenuk and the American Academy of Ophthalmology (AAO) reported Oct. 16 that they had teamed up under the AAO’s EyeCare America program to provide eye disease screening for underserved communities ...

First ASCRS Business Summit Breaks Down Premium Surgery’s Role in Practice Success
First ASCRS Business Summit Breaks Down Premium Surgery’s Role in Practice Success

The first-ever ASCRS Business of Refractive Cataract Surgery (BRiCS) Summit was a two-day course designed to equip practices with the knowledge, resources, and confidence to boost their adoption of...

US FDA Grants 510(k) Clearance to Flex Module for Heidelberg Spectralis OCT
US FDA Grants 510(k) Clearance to Flex Module for Heidelberg Spectralis OCT

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

Orasis Licenses Qlosi Presbyopia Drops to Optus in Korea for $18 Million, Plus Royalties
Orasis Licenses Qlosi Presbyopia Drops to Optus in Korea for $18 Million, Plus Royalties

Orasis Pharmaceuticals announced Oct. 16 that it had licensed its Qlosi presbyopia drops to Optus Pharmaceuticals for the Korean market. Under the deal, Optus will pay upfront and milestone payment...

Nicox and Soleus Sign $16.5 Million Deal for Vyzulta Royalties, Equity Financing
Nicox and Soleus Sign $16.5 Million Deal for Vyzulta Royalties, Equity Financing

France’s Nicox announced Oct. 14 a deal with Soleus Capital under which Soleus will acquire Nicox’ royalties from the glaucoma treatment Vyzulta for $15 million, while providing $1.5 million in equ...

Cure Blindness Project Expands Sight-Saving Care to Six New Countries
Cure Blindness Project Expands Sight-Saving Care to Six New Countries

Cure Blindness Project is expanding to six new countries—Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia, the charity reported Oct. 10. Paraguay marksthe charity’...

Lensar Marks 1 Million Procedures Using its Femtosecond Cataract Lasers
Lensar Marks 1 Million Procedures Using its Femtosecond Cataract Lasers

Lensar reported Oct. 8 that surgeons had performed more than 1 million procedures using its Lensar femtosecond cataract systems. The Orlando, Florida, company introduced its original Lensar Laser S...

EU Grants Orphan Drug Status to Theriva’s Retinoblastoma Candidate
EU Grants Orphan Drug Status to Theriva’s Retinoblastoma Candidate

Theriva Biologics, of Rockville, Maryland, announced Oct. 16 that the European Commission had granted orphan medicinal product designation for VCN-01, its treatment candidate for retinoblastoma. VC...

ESCRS Congress Boasts Record Attendance in Barcelona
ESCRS Congress Boasts Record Attendance in Barcelona

Barcelona, Spain, hosted the ESCRS congress for the third time in the 42-year history of the meeting and set a record for the highest attendance to date. Nearly 17 thousand people registered, 60 pe...

EU Regulators Rain on Apellis’ Party at 2024 Euretina Congress
EU Regulators Rain on Apellis’ Party at 2024 Euretina Congress

The big news at the 24th Euretina congress was something that didn’t happen at the congress. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) embarrassed Apelli...

Zeiss Begins Broad US Rollout of Micor 700 for Phaco-less Cataract Surgery
Zeiss Begins Broad US Rollout of Micor 700 for Phaco-less Cataract Surgery

Zeiss Medical Technology reported Sept. 26 that it had begun broad US distribution of the Micor 700, the first hand-held device to extract a crystalline lens in cataract surgery without the need fo...

Eyenovia Launches Clobetasol Drops for Postoperative Pain and Inflammation
Eyenovia Launches Clobetasol Drops for Postoperative Pain and Inflammation

Eyenovia announced Sept. 26 the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, known as Clobetasol, for postoperative inflammation and pain following oc...

Orasis Leads Latest Ophthalmic Deals with $78 Million Financing
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing

Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...

AbbVie Withdraws EU Marketing Application for Durysta Implant for Glaucoma
AbbVie Withdraws EU Marketing Application for Durysta Implant for Glaucoma

Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...

Select US FDA Approvals and Clearances in September 2024
Select US FDA Approvals and Clearances in September 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in September 2024, according to the agency’s database. Zeiss gained clearance for its combination Y...

NEI Researchers Identify Protein That Clears Cataracts in Animals
NEI Researchers Identify Protein That Clears Cataracts in Animals

Researchers at the National Eye Institute (NEI), working with counterparts in China, have discovered a reversible cataract response in hibernating squirrels that may point toward a nonsurgical trea...

Emerging Companies Pursuing Ophthalmic Indications, October 2024
Emerging Companies Pursuing Ophthalmic Indications, October 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Aurion Biotech Launches Vyznova Corneal Cell Therapy in Japan
Aurion Biotech Launches Vyznova Corneal Cell Therapy in Japan

Aurion Biotech announced Sept. 24 that it had launched Vyznova (neltependocel), a cell therapy for bullous keratopathy of the cornea, in Japan. Japanese regulators approved Vyznova in March 2023. T...

Retina Specialists Grapple with Functional Endpoints in Clinical Trials
Retina Specialists Grapple with Functional Endpoints in Clinical Trials

European regulators’ repeated rejection of Syfovre made one thing very clear to retina specialists at Euretina: “Treatment should have an impact on everyday function,” said Thomas Ach, MD (Germany)...

Retina Surgeons at European Meetings Ask, ‘What’s New?’
Retina Surgeons at European Meetings Ask, ‘What’s New?’

Experienced retina surgeons among the approximately 8.1 thousand attendees at Euretina in Barcelona, Spain, were underwhelmed by the surgical devices that industry had on display. “There is nothing...

First GA Therapies at Crossroads as EU Regulators Unconvinced Benefits Outweigh Risks
First GA Therapies at Crossroads as EU Regulators Unconvinced Benefits Outweigh Risks

The negative opinion of Syfovre by a key EU regulatory committee has thrown the global marketing plans for complement inhibitors for GA into disarray. Two companies—Apellis Pharmaceuticals and Aste...

ESCRS iNovation Day Looks at MDR Roadblocks, Global Care Issues
ESCRS iNovation Day Looks at MDR Roadblocks, Global Care Issues

The impact of Europe’s new Medical Device Regulation (MDR) on innovation sparked considerable discussion during the ESCRS iNovation Day. The meeting was held Sept. 6 in Barcelona, Spain, ahead of t...

ISOP Meeting Examines Importance of Patient Education and Predictable Outcomes
ISOP Meeting Examines Importance of Patient Education and Predictable Outcomes

Patient selection, education, and communication were emphasized throughout the International Society of Presbyopia’s 16th annual conference. The meeting, held Sept. 5 at the Hyatt Regency Hotel in ...

Sustainability: Walking the Walk or Talking the Talk?
Sustainability: Walking the Walk or Talking the Talk?

Sustainability was a theme for multiple sessions at this year’s ESCRS congress, including one called “Sustainability Without Borders,” hosted by the ESCRS’ Young Ophthalmologists for Sustainability...

Investors Take Temperature of Ophthalmic Market at European Futures Forum
Investors Take Temperature of Ophthalmic Market at European Futures Forum

The 2024 Ophthalmology Futures European Forum reviewed the decline in ophthalmic deals in 2024 before offering presenting companies some guidance on how to advance their technology in such an envir...

Hyperopia Treatment Using Lenticule Extraction Showcased to Eager European Ophthalmologists
Hyperopia Treatment Using Lenticule Extraction Showcased to Eager European Ophthalmologists

Dan Reinstein, MD (UK), shared during an overly full symposium at the 2024 ESCRS congress his experience using Zeiss’ SMILE lenticule extraction procedure to treat hyperopic patients. Zeiss is the ...

Cornea Surgeons Examine New Crosslinking Options and Old Debates
Cornea Surgeons Examine New Crosslinking Options and Old Debates

Farhad Hafezi, MD, PhD, FARVO (Switzerland), discussed at the 2024 ESCRS congress the goals of the second global consensus on keratoconus, being drafted in 2024. This consensus encompasses feedback...

ESCRS Congress Celebrates 75th Anniversary of First IOL Implantation
ESCRS Congress Celebrates 75th Anniversary of First IOL Implantation

The 2024 ESCRS congress celebrated the 75th anniversary of Sir Harold Ridley, MD, implanting the first intraocular lens by telling his story and describing the developments that have occurred since...

2024 ESCRS Congress Puts Spotlight on Latest IOL Designs
2024 ESCRS Congress Puts Spotlight on Latest IOL Designs

New and recently launched IOLs took the spotlight in presentations and on the exhibit floor at the 2024 ESCRS congress. These lenses included the Rayner RayOne Galaxy trifocal, the BVI Serenity Mon...

ViaLase Releases Latest Glaucoma Laser Data at ESCRS Congress
ViaLase Releases Latest Glaucoma Laser Data at ESCRS Congress

Rick Lewis, MD, chief medical officer at ViaLase, provided an update at the 2024 ESCRS congress on the ViaLuxe glaucoma laser, including the system’s most recent clinical trial results. The ViaLuxe...

Bausch + Lomb Launches Octavius Topo-Guided Treatment at ESCRS Congress
Bausch + Lomb Launches Octavius Topo-Guided Treatment at ESCRS Congress

Bausch + Lomb showcased its CE marked Octavius at the 2024 ESCRS Congress. Octavius is a new treatment mode on the Teneo excimer laser that uses data from multiple diagnostic platforms to provide a...

Clinical Trial Updates for Ophthalmic Candidates, October 2024
Clinical Trial Updates for Ophthalmic Candidates, October 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Zeiss Invests $24 Million to Expand Production Site in Chesterfield, Missouri
Zeiss Invests $24 Million to Expand Production Site in Chesterfield, Missouri

German company Carl Zeiss Meditec opened a new state-of-the-art research and production facility on Oct. 1 in Chesterfield, Missouri, expanding its footprint in the city, which is part of the St. L...

Harrow to Add Nearly 150 Jobs as it Expands in Nashville, Relaunches Triesence
Harrow to Add Nearly 150 Jobs as it Expands in Nashville, Relaunches Triesence

Harrow reported Sept. 25 that it is creating nearly 150 new jobs as it expands its corporate headquarters in Nashville, Tennessee. The move follows the company increasing its total leased space in ...

Europe’s CHMP Recommends Two Aflibercept Biosimilars for Approval
Europe’s CHMP Recommends Two Aflibercept Biosimilars for Approval

Europe’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions on Sept. 19 for two new aflibercept (Eylea) biosimilars—Afqlir from Swiss drugmaker Sandoz and Opuviz, which ...

FTC Sends More Than $1.1 Million to Consumers Misled by LCA-Vision Ads
FTC Sends More Than $1.1 Million to Consumers Misled by LCA-Vision Ads

The Federal Trade Commission (FTC) announced Oct. 3 that it was sending more than $1.1 million in settlement payments to consumers who were misled by deceptive bait-and-switch advertising by LCA-Vi...

October 2024 Ophthalmic News Briefs
October 2024 Ophthalmic News Briefs

Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...

NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan
NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan

NovaBay Pharmaceuticals has agreed to sell its Avenova products to PRN Physician Recommended Nutriceuticals for $9.5 million in cash, the companies announced Sept. 20. The deal is expected to close...

Weekly Surgeon Poll, October 2024
Weekly Surgeon Poll, October 2024

FDA Names New Leaders at OPEQ and CDHR
FDA Names New Leaders at OPEQ and CDHR

Ross Segan, MD, MBA, FACS, has become director of the US FDA’s Office of Product Evaluation and Quality (OPEQ). The office, part of FDA’s Center for Devices and Radiological Health (CDRH), oversees...

Aldeyra Resubmits NDA for Reproxalap in Dry Eye
Aldeyra Resubmits NDA for Reproxalap in Dry Eye

Aldeyra Therapeutics announced Oct. 3 that it had resubmitted its new drug application (NDA) to the US FDA for topical ocular reproxalap in dry eye. The US FDA issued a complete response letter in ...

Nanoscope Plans to Submit BLA for Optogenetic RP Candidate in Q1-2025
Nanoscope Plans to Submit BLA for Optogenetic RP Candidate in Q1-2025

Nanoscope Therapeutics announced Oct. 10 that it had met with the US FDA regarding MCO-010, an ambient-light-activatable optogenetic monotherapy to restore vision in patients with advanced retiniti...

FTC Sends More Than $1.1 Million to Consumers Misled by LCA-Vision Ads
FTC Sends More Than $1.1 Million to Consumers Misled by LCA-Vision Ads

The Federal Trade Commission (FTC) announced Oct. 3 that it was sending more than $1.1 million in settlement payments to consumers who were misled by deceptive bait-and-switch advertising by LCA-Vi...

Rayner Begins US Study of RayOne Galaxy Trifocal Spiral IOL
Rayner Begins US Study of RayOne Galaxy Trifocal Spiral IOL

UK-based Rayner reported Oct. 1 that the first RayOne Galaxy lenses had been implanted in the US as part of an FDA investigational device exemption (IDE) study. Rayner describes the Galaxy, a trifo...

US FDA Removes Clinical Hold on Ocugen’s IND for OCU200 in DME
US FDA Removes Clinical Hold on Ocugen’s IND for OCU200 in DME

Ocugen announced Oct. 9 that the US FDA had lifted its clinical hold on the investigational new drug (IND) application for a Phase I trial of OCU200, a recombinant fusion protein consisting of tums...

Beyeonics One Introduces ‘Invisible Light’ Infrared Illumination
Beyeonics One Introduces ‘Invisible Light’ Infrared Illumination

Israel’s Beyeonics Vision announced Oct. 8 that it had incorporated “invisible light” technology, based on infrared night vision, into the Beyeonics One surgical visualization system. Beyeonics sai...

iCare Launches ST500 Slit Lamp Mounted Rebound Tonometer
iCare Launches ST500 Slit Lamp Mounted Rebound Tonometer

Finland’s iCare, a subsidiary of Revenio Group, has launched its iCare ST500 rebound tonometer that can be attached to a slit lamp. The device gained US FDA 510(k) clearance on Sept. 27. The compan...

Iridex Appoints Patrick Mercer as Chief Executive Officer
Iridex Appoints Patrick Mercer as Chief Executive Officer

Iridex reported Oct. 3 that it had appointed Patrick Mercer as chief executive officer, to go along with his role as president, effective Oct. 1. Mercer had also served as the company’s chief opera...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more